Business News

Mestastop Solutions Inc. Launches Breakthrough Platforms to Improve Cancer Survival

Biotechnology company Mestastop Solutions has created three platforms to address cancer metastasis drug discovery and predictive diagnostic bottlenecks. These platforms have been successfully applied to drug repurposing and predictive diagnostics. The drug repurposing results were validated in retrospective clinical studies, while the predictive diagnostics were validated in a prospective study. Collectively, these results represent a breakthrough in drug discovery and predictive diagnostics that offers new hope for cancer patients and their families. 

John Ellingboe, PhD, Director of Mestastop, said, “Addressing the problem of metastasis is the most promising way to improve the overall survival chances of cancer patients. Our platforms have performed beyond expectations in the initial proof of concept studies.

Mestastop focuses exclusively on research and development in the area of cancer metastasis. Its first platform, METAssay™, helped to identify three drugs approved for non-cancer indications that influence metastasis. A follow-up retrospective clinical study of one hundred colorectal cancer patients confirmed the rank ordering of these compounds and their positive effect on survival. 

Among reasons for drug discovery failure around metastasis have been the limited focus on the late stages of the metastatic process and on metastatic tumor cells. Mestastop’s platforms along with clinical data have highlighted the importance of these steps and the relevance of an elusive population of moving cells. 

The company’s second platform, METSCAN™, helped to identify rate-limiting critical steps of metastasis, and subsequently, novel, first-in-class targets. The first target has been validated by genetic engineering and a tool compound and is ready for a discovery program. Additionally, when clinicians begin using the METSCAN™ platform as a companion diagnostic tool to identify primary tumor patients at a higher risk of metastasis, they will have…


Source link

Related Articles

Back to top button